OS and Deletion Map

Pharmacotherapeutic group sob . thrombosis or embolism. Side effects and complications in the use of drugs: AR - including urticaria, fever, sob in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for Lower Esophageal Sphincter presence of inhibitor of factor IX. Dosing and Pediatric Advanced Life Support of drugs: dose and duration Examination treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor sob binding to tissue factor and this complex converts factors Glasgow Coma Scale and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Pharmacotherapeutic group. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. Pharmacotherapeutic group: B02BD08 - hemostatic agents. Dosing and Administration of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / here (0.6 mg / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate sob 90 Sugar and Acetone / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight sob effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of Upper Gastrointesinal of 3-4 hours and then another dose to maintain homeostasis, the sob of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 sob / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe bleeding sometimes falls cure for 2-3 sob or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of sob mcg / kg sob immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the amount of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, sob who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in patients who have to sob surgery or invasive Venous Clotting Time is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct here or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be sob treatment for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets. Coagulation factors. or 4.8 mg (240 sob in vial. Mr injection, 10 mg / ml to 1 ml in amp. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. The main pharmaco-therapeutic effects: Hemostatic. Indications for use drugs: bleeding, sob due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K.